General Information of Drug (ID: DMAU79Q)

Drug Name
IDEC-131 Drug Info
Indication
Disease Entry ICD 11 Status REF
Thrombocytopenia 3B64 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMAU79Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IL-2/CD40L-expressing leukemia vaccine DMIHQ5G Chronic lymphocytic leukaemia 2A82.0 Phase 2 [3]
BI 655064 DMF86P2 Lupus 4A40 Phase 2 [4]
Lucatumumab DMY2L7V Lymphoma 2A80-2A86 Phase 2 [5]
Dapirolizumab pegol DMIYFWA Systemic lupus erythematosus 4A40.0 Phase 2 [6]
PG-102 DMF5YEN Autoimmune diabetes 5A10 Phase 2 [7]
ISF35 DMBZK3P Chronic lymphocytic leukaemia 2A82.0 Phase 2 [8]
CDP-7657 DMN8I5Q Systemic lupus erythematosus 4A40.0 Phase 1 [9]
MEDI4920 DME7BMT Rheumatoid arthritis FA20 Phase 1 [10]
UltraCD40L DMHG7DZ Systemic lupus erythematosus 4A40.0 Phase 1 [11]
BPX-101 DM51MSD Prostate cancer 2C82.0 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TNF related activation protein (CD40LG) TTIJP3Q CD40L_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007783)
2 Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan;28(1):95-101.
3 Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
4 FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
5 Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
8 Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
9 CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
10 ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
11 CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
12 Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.